ArticleEuropean child & adolescent psychiatry2026
The development and validation of the questionnaire My Experience with ADHD Pharmacotherapy - Parent Report (ME WAPH-P).
Article in European child & adolescent psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonadherence to pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) is common among children and adolescents. Despite well-documented clinical and contextual barriers, to the best of our knowledge no dedicated tool exists to quantify parental challenges in supporting adherence. This study aimed to develop and evaluate the My Experience with ADHD Pharmacotherapy - Parent Report (ME WAPH-P) questionnaire. The ME WAPH-P was developed based on existing instruments, clinical experience, expert input, and literature on nonadherence. The initial 30-item questionnaire assessed adherence-related challenges across six subscales. Parents of children aged 4-18 years who had received ADHD medication were recruited via social media and a commercial survey platform. The final sample included 351 parents. Psychometric evaluation included internal consistency, item discrimination, subscale intercorrelations, and exploratory factor analysis (oblique rotation). After removing one item, the 29-item scale demonstrated excellent internal consistency (Cronbach's α = 0.90). Subscale reliability demonstrated moderate-to-high intercorrelations. Parallel analysis supported a three-factor structure explaining 44.7% of variance, with moderately correlated factors and some cross-loadings. Parents' primary concerns focused on adverse effects, doubts about effectiveness and safety, summer treatment breaks, and child resistance. Parents of children treated for less than one year reported significantly higher challenge scores, supporting criterion validity. The current preliminary study supports the potential of the ME WAPH-P in capturing a broad, multidimensional construct of parental challenges in ADHD medication adherence. Findings highlighted child resistance as an underexplored barrier. The dimensionality of the questionnaire construct suggests a cumulative "adherence burden". This novel tool may support clinical identification and monitoring of adherence challenges with implications for targeted clinical intervention.
Indexed as
Identifiers
42565880What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.